Compass Therapeutics (CMPX) News Today $1.56 -0.14 (-7.99%) As of 10:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Leerink Partners Upgrades Compass Therapeutics (CMPX)April 3 at 3:27 AM | msn.comCompass Therapeutics (CMPX) Receives a Buy from GuggenheimApril 3 at 3:27 AM | markets.businessinsider.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and sApril 3 at 2:38 AM | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Earns Outperform Rating from WedbushApril 3 at 1:49 AM | americanbankingnews.comCompass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology ForumApril 2 at 4:05 PM | globenewswire.comCompass Therapeutics says tovecimig meets primary endpoint in Phase 2/3 studyApril 2 at 1:52 PM | markets.businessinsider.comInvestors Buy Large Volume of Compass Therapeutics Put Options (NASDAQ:CMPX)Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) saw unusually large options trading on Tuesday. Stock traders acquired 22,702 put options on the company. This is an increase of approximately 797% compared to the average volume of 2,532 put options.April 2 at 11:43 AM | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 24.6% in MarchCompass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 4,610,000 shares, a growth of 24.6% from the February 28th total of 3,700,000 shares. Based on an average daily volume of 1,440,000 shares, the short-interest ratio is currently 3.2 days. Currently, 5.7% of the company's shares are sold short.April 2 at 9:00 AM | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Given "Buy" Rating at D. Boral CapitalD. Boral Capital reissued a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a report on Tuesday.April 2 at 8:02 AM | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Receives "Buy" Rating from D. Boral CapitalApril 2 at 4:15 AM | americanbankingnews.comTraders Buy Large Volume of Put Options on Compass Therapeutics (NASDAQ:CMPX)April 2 at 1:33 AM | americanbankingnews.comCompass Therapeutics posts clinical trial win for biliary tract cancer therapyApril 1 at 12:32 PM | msn.comTovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract CancerApril 1 at 7:00 AM | globenewswire.comCompass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract CancerMarch 31 at 4:05 PM | globenewswire.comWith 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interestMarch 18, 2025 | finance.yahoo.comCompass Therapeutics (CMPX) Projected to Post Earnings on ThursdayCompass Therapeutics (NASDAQ:CMPX) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have earned an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating and seven have given a buy ratiMarch 8, 2025 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest UpdateCompass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) saw a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 3,530,000 shares, a growth of 28.4% from the January 31st total of 2,750,000 shares. Currently, 4.4% of the shares of the company are sold short. Based on an average trading volume of 1,330,000 shares, the days-to-cover ratio is presently 2.7 days.March 5, 2025 | marketbeat.comResearch Analysts Issue Forecasts for CMPX Q1 EarningsCompass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Compass Therapeutics in a report released on Thursday, February 27th. HC Wainwright analyst J. Pantginis anticipates that the company will poMarch 3, 2025 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPSCompass Therapeutics (NASDAQ:CMPX - Get Free Report) announced its earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01).February 28, 2025 | marketbeat.comCompass Therapeutics shares rise on pipeline progressFebruary 28, 2025 | za.investing.comCompass Therapeutics reports Q4 EPS (11c), consensus (9c)February 28, 2025 | markets.businessinsider.comCompass Therapeutics sees cash runway into 1Q27February 28, 2025 | markets.businessinsider.comCompass Therapeutics Reports 2024 Financial Results and Provides Corporate UpdateFebruary 27, 2025 | globenewswire.comCompass Therapeutics' (CMPX) Buy Rating Reiterated at D. Boral CapitalD. Boral Capital restated a "buy" rating and issued a $32.00 price objective on shares of Compass Therapeutics in a report on Tuesday.February 25, 2025 | marketbeat.comGuggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy RecommendationFebruary 25, 2025 | msn.comCompass Therapeutics initiated with a Buy at GuggenheimFebruary 24, 2025 | markets.businessinsider.comCompass Therapeutics (NASDAQ:CMPX) Coverage Initiated at GuggenheimGuggenheim initiated coverage on shares of Compass Therapeutics in a research note on Monday. They set a "buy" rating and a $12.00 price objective on the stock.February 24, 2025 | marketbeat.comPiper Sandler Initiates Coverage of Compass Therapeutics (CMPX) with Overweight RecommendationFebruary 20, 2025 | msn.comPiper Sandler Begins Coverage on Compass Therapeutics (NASDAQ:CMPX)Piper Sandler initiated coverage on shares of Compass Therapeutics in a report on Wednesday. They issued an "overweight" rating and a $12.00 price target for the company.February 20, 2025 | marketbeat.comTwo new option listings on February 11thFebruary 12, 2025 | markets.businessinsider.comCompass Therapeutics (NASDAQ:CMPX) Stock Price Down 7.6% - Here's WhyCompass Therapeutics (NASDAQ:CMPX) Stock Price Down 7.6% - Time to Sell?February 11, 2025 | marketbeat.comCompass Therapeutics price target raised to $8 from $7 at JefferiesFebruary 11, 2025 | markets.businessinsider.comCompass Therapeutics (NASDAQ:CMPX) Stock Price Expected to Rise, Jefferies Financial Group Analyst SaysJefferies Financial Group raised their price target on Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Monday.February 10, 2025 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Sets New 52-Week High - Time to Buy?Compass Therapeutics (NASDAQ:CMPX) Hits New 1-Year High - Still a Buy?February 10, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for CMPX FY2024 Earnings?Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Equities researchers at Leerink Partnrs raised their FY2024 earnings estimates for shares of Compass Therapeutics in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now expects that the company will poFebruary 10, 2025 | marketbeat.comWhy Compass Therapeutics Inc (CMPX) Is Skyrocketing So Far In 2025February 4, 2025 | msn.comTop 3 High-Momentum Companies Analysts Are Still Bullish OnMomentum investors seek to take advantage of share price rallies to buy companies before they peak; analysts think these three firms still have room to grow.February 4, 2025 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Shares Purchased by SG Americas Securities LLCSG Americas Securities LLC raised its holdings in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 921.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 395,017 shares of the company's sFebruary 1, 2025 | marketbeat.comCompass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | markets.businessinsider.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Shares Acquired by Barclays PLCBarclays PLC increased its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 195.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 170,245 shares of the company's stock after purchasing aJanuary 20, 2025 | marketbeat.comShort Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Grows By 5.2%Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,210,000 shares, an increase of 5.2% from the December 15th total of 2,100,000 shares. Currently, 2.6% of the company's stock are short sold. Based on an average daily volume of 875,000 shares, the days-to-cover ratio is presently 2.5 days.January 19, 2025 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Moderate Buy" from AnalystsCompass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has been given an average rating of "Moderate Buy" by the six research firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on theJanuary 17, 2025 | marketbeat.comCompass Therapeutics stock hits 52-week high at $2.68January 16, 2025 | msn.comCompass Therapeutics: Strategic Advancements and Promising Pipeline Justify Buy RatingJanuary 9, 2025 | markets.businessinsider.comCompass Therapeutics: Strong Growth Potential Bolstered by Upcoming Milestones and Strategic FocusJanuary 8, 2025 | markets.businessinsider.comAnother Day, Another Biotech Stealing The ShowJanuary 8, 2025 | msn.comCompass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug CandidateJanuary 8, 2025 | finance.yahoo.comCompass Therapeutics (NASDAQ:CMPX) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Compass Therapeutics in a research report on Wednesday.January 8, 2025 | marketbeat.comCompass Therapeutics initiated with a Buy at D. Boral CapitalDecember 24, 2024 | markets.businessinsider.com Remove Ads Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address CMPX Media Mentions By Week CMPX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMPX News Sentiment▼0.420.57▲Average Medical News Sentiment CMPX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMPX Articles This Week▼222▲CMPX Articles Average Week Remove Ads Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MLYS News GPCR News SYRE News ELVN News COLL News NRIX News VIR News PAHC News XERS News OCS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMPX) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CMPX Stock Free CMPX Stock Alerts